Approval · Notice of Compliance 8056 · 2006
HUMIRA: Notice of Compliance 8056
Issued June 20, 2006
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 8056
- Date
- June 20, 2006
- Company
- Abbott Laboratories Co.Saint-Laurent, Quebec, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New indication: reducing the signs and symptoms of active arthritis in adult psoriatic arthritis patients. humira can be used in combination with methotrexate in patients who do not respond adequately to methotrexate alone
- Therapeutic class
- Biological response modifier
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| HUMIRA | Not yet assigned | — |
Medicinal ingredients
- ADALIMUMAB 40 MG per 0.8ML